Cesaro, S, Garonzi, C, Tridello, G, Verheggen, I, Liu, DH, Flynn, C, Alahmari, A, Kaynar, L, Rabitsch, W, Uygun, V, Chorao, P, Hu, J, Esquirol, A, Piñana, JL, Aljurf, M, Wagner-Drouet, E, Lang, PT, Martin-Sanchez, G, Ratip, S, Facchini, L, Nasilowska-Adamska, B, Styczynski, J, Ram, R, Metafuni, E, Tanase, A, Kalwak, K, Serio, B, Hashem, H, Castagna, L, Vicent, MG, Karakukcu, M, Halahleh, K, Baltadakis, I, Benedetti, E, Mikulska, M, de la Camara, R, Averbuch, D. Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT. BONE MARROW TRANSPLANTATION. 2026; 61(5)DOI:10.1038/s41409-026-02832-1. PMID:41888297. IF:5.200(Q1/1D).

García-Cadenas, I, Guerreiro, M, Yañez, L, Chorao, P, Martin, F, Suárez-Lledó, M, Pérez, A, Tomás, LG, López, J, Marsal, J, Romero, N, Huguet, M, Zabalza, A, González-Vicent, M, Vázquez, L, Silva, P, Gil, D, Micó-Cerdà, M, Sánchez, P, Filaferro, S, Balsalobre, P, Jiménez-Ubieto, A, Martino, R, Piñana, JL. Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(4)DOI:10.1111/ejh.70109. PMID:41502050. IF:2.300(Q2/5D).

Mikulska, M, Tridello, G, Ljungman, P, Styczynski, J, Averbuch, D, Cesaro, S, Knelange, N, Wendel, L, Piñana, JL, Popova, M, Kröger, N, Sengeloev, H, Besley, C, Labussiere-Wallet, H, Yegin, ZA, Greco, R, Baron, F, Yonal-Hindilerden, I, Xhaard, A, Metafuni, E, Verbeek, M, Byrne, J, Toprak, SK, Grassi, A, Vallisa, D, Clay, J, Bufarull, RM, Van Gorkom, G, Sevindik, OG, Wilson, K, de la Camara, R. Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study. BONE MARROW TRANSPLANTATION. 2026; 61(4)DOI:10.1038/s41409-026-02819-y. PMID:41795056. IF:5.200(Q1/1D).

Hidalgo-Soto, M, Rodríguez-Lobato, LG, Borrella, CM, Cayuela, AS, Pardo, JL, Rosiñol, L, Cibeira, MT, García-Guiñon, A, Tolosa-Ridao, C, Arostegui, IC, Sureda, A, Herranz, MJ, Montreal, EA, Pelicano, M, Alzuria, YB, Sansa, MC, Gironella, M, González, Y, De Larrea, CF. Pomalidomide, Cyclophosphamide and Dexamethasone (PCd): Outcomes in Patients With Double- or Triple-Refractory Multiple Myeloma. EUROPEAN JOURNAL OF HAEMATOLOGY. 2026; 116(6)DOI:10.1111/ejh.70126. PMID:41652820. IF:2.300(Q2/5D).

Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).

Domínguez, JMG, Villar, LM, Arrambide, G, Blanco, Y, Calles, MC, Casanova, B, Castillo-Triviño, T, França, LCF, Eichau, S, Pérez, MAH, Landete, L, Lallana, JM, Oreja-Guevara, C, Prieto, JM, Querol, L, Caminero, AB. Relevance of serum neurofilament light chain determination as a biomarker in multiple sclerosis. Consensus of the Spanish Society of Neurology's Study Group on Multiple Sclerosis and Related Neuroimmune Diseases. NEUROLOGIA. 2026; 41(4)DOI:10.1016/j.nrl.2025.501928. PMID:. IF:3.100(Q2/4D).

Kleefeld, F, Gamboa, JT, Pinal-Fernandez, I, Preusse, C, Nelke, C, Goebel, HH, Mensch, A, Mossakowski, A, Miah, MU, Diaz-Manera, J, Torchia, E, Bortolani, S, Hentschel, A, Funke, A, Souvannanorath, S, Authier, FJ, Malfatti, E, Gehrig, J, Mammen, AL, Casal-Dominguez, M, De Winter, J, De Ridder, W, Ruck, T, Schneider, U, Roos, A, Gallardo, E, Tasca, G, Stenzel, W. Brachio-cervical inflammatory myopathy: multilevel clinical, histopathological and multi-omic analyses of a syndrome variably associated with systemic sclerosis. ACTA NEUROPATHOLOGICA. 2026; 151(1)DOI:10.1007/s00401-026-03006-5. PMID:41934478. IF:9.300(Q1/1D).

Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. ADVANCES IN THERAPY. 2026; 43(4)DOI:10.1007/s12325-026-03490-x. PMID:41591648. IF:4.000(Q1/3D).